Adial Pharmaceuticals Inc (ADIL)

$2.33 -0.22 (-8.63%)
Market Cap 5.81M
Revenue (ttm) 0.00
Net Income (ttm) -7.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 62,439
Avg Vol 571,352
Day's Range N/A - N/A
Shares Out 2.14M
Stochastic %K 14%
Beta 1.46
Analysts Sell
Price Target $8.00

Company Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen...

Industry: Biotechnology
Sector: Healthcare
Phone: 804 487 8196
Address:
4870 Sadler Road, Suite 300, Glen Allen, United States
blackmajic31
blackmajic31 Jun. 24 at 11:51 AM
$ADIL
0 · Reply
StayPresent
StayPresent Jun. 23 at 7:18 PM
$ADIL I think Claiborne might be waiting for reparations or something to help fund this pos company.
1 · Reply
brallt
brallt Jun. 22 at 2:19 PM
$ADIL She gets Jucy over 3.20.
1 · Reply
Freeton
Freeton Jun. 18 at 7:39 PM
$ADIL why?
0 · Reply
brallt
brallt Jun. 18 at 5:15 PM
$ADIL about a 10% move to 3$ resistance.
0 · Reply
brallt
brallt Jun. 18 at 4:26 PM
$ADIL around time for todays accumulation. giving a bit more for lunch to be over.
0 · Reply
specctham
specctham Jun. 18 at 2:02 PM
$ADIL I want to buy a shitload of shares in this, but im scared.
0 · Reply
brallt
brallt Jun. 17 at 5:47 PM
$ADIL # fomo, am i not going to get my dip?.....
0 · Reply
Vibration
Vibration Jun. 17 at 5:16 PM
$ADIL it should pop in 5 min or back to the scalp !
0 · Reply
brallt
brallt Jun. 17 at 5:10 PM
$ADIL keep an eye out for a short attack to buy more before the move over 3 comes.
0 · Reply
Latest News on ADIL
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing

Jun 16, 2026, 8:00 AM EDT - 8 days ago

Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing

Adial Pharmaceuticals initiated with a Buy at Lucid Capital

2026-06-15T10:11:49.000Z - 9 days ago

Adial Pharmaceuticals initiated with a Buy at Lucid Capital

Adial Pharmaceuticals Press release: M&A announcement

Jun 11, 2026, 1:00 PM EDT - 13 days ago

Adial Pharmaceuticals Press release: M&A announcement

Adial Pharmaceuticals announces acquisition of Azora Therapeutics

2026-06-11T15:50:09.000Z - 13 days ago

Adial Pharmaceuticals announces acquisition of Azora Therapeutics

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Jun 11, 2026, 11:43 AM EDT - 13 days ago

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals Slides: Corporate presentation

Jun 11, 2026, 7:00 AM EDT - 13 days ago

Adial Pharmaceuticals Slides: Corporate presentation

Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update

May 11, 2026, 8:30 AM EDT - 6 weeks ago

Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update

Adial Pharmaceuticals Quarterly report: Q1 2026

May 8, 2026, 8:00 AM EDT - 6 weeks ago

Adial Pharmaceuticals Quarterly report: Q1 2026

Adial Pharmaceuticals Earnings release: Q1 2026

May 8, 2026, 8:00 AM EDT - 6 weeks ago

Adial Pharmaceuticals Earnings release: Q1 2026

Adial Pharmaceuticals files AD04 utility application with USPTO

2026-04-29T16:56:08.000Z - 2 months ago

Adial Pharmaceuticals files AD04 utility application with USPTO

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045

Apr 29, 2026, 9:07 AM EDT - 2 months ago

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045

Adial submits AD04 product application for FDA CNPV pilot program

2026-04-27T13:29:38.000Z - 2 months ago

Adial submits AD04 product application for FDA CNPV pilot program

Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program

Apr 27, 2026, 8:47 AM EDT - 2 months ago

Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program

Adial Pharmaceuticals completes AD04 demonstration batch production

2026-04-22T13:57:56.000Z - 2 months ago

Adial Pharmaceuticals completes AD04 demonstration batch production

Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial

Apr 22, 2026, 9:35 AM EDT - 2 months ago

Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial

Adial Pharmaceuticals expects cash to fund operations into 2H of 2026

2026-03-06T13:06:13.000Z - 3 months ago

Adial Pharmaceuticals expects cash to fund operations into 2H of 2026

Adial Pharmaceuticals Annual report: Q4 2025

Mar 5, 2026, 7:00 AM EST - 3 months ago

Adial Pharmaceuticals Annual report: Q4 2025

Adial Pharmaceuticals Earnings release: Q4 2025

Mar 5, 2026, 7:00 AM EST - 3 months ago

Adial Pharmaceuticals Earnings release: Q4 2025

Adial Pharmaceuticals enters collaboration framework agreement with Molteni

2026-03-03T13:35:20.000Z - 4 months ago

Adial Pharmaceuticals enters collaboration framework agreement with Molteni

Adial Pharmaceuticals Slides: Investor presentation

Feb 26, 2026, 7:00 AM EST - 4 months ago

Adial Pharmaceuticals Slides: Investor presentation

Adial Pharmaceuticals regains compliance with Nasdaq listing requirement

2026-02-24T14:07:23.000Z - 4 months ago

Adial Pharmaceuticals regains compliance with Nasdaq listing requirement

Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement

Feb 24, 2026, 9:00 AM EST - 4 months ago

Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement

Adial Pharmaceuticals highlights recent FDA policy, may reduce trial burden

2026-02-23T13:48:10.000Z - 4 months ago

Adial Pharmaceuticals highlights recent FDA policy, may reduce trial burden

Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One

Feb 23, 2026, 8:30 AM EST - 4 months ago

Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One

Adial Pharmaceuticals price target lowered to $8 from $37.50 at Maxim

2026-02-11T13:46:03.000Z - 4 months ago

Adial Pharmaceuticals price target lowered to $8 from $37.50 at Maxim

Adial Pharmaceuticals trading halted, news pending

2026-02-06T00:50:11.000Z - 4 months ago

Adial Pharmaceuticals trading halted, news pending

Why Is Adial Pharmaceuticals Stock (ADIL) Down Today?

2026-02-05T14:38:47.000Z - 4 months ago

Why Is Adial Pharmaceuticals Stock (ADIL) Down Today?

Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

Feb 4, 2026, 9:35 AM EST - 5 months ago

Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

Adial Pharmaceuticals announces 1-for-25 reverse stock split

2026-02-03T22:05:26.000Z - 5 months ago

Adial Pharmaceuticals announces 1-for-25 reverse stock split

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Feb 3, 2026, 4:05 PM EST - 5 months ago

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Adial announces publication of international patent application for AD04

2026-01-14T14:05:52.000Z - 5 months ago

Adial announces publication of international patent application for AD04

Adial Pharmaceuticals Proxy statement: Proxy filing

Jan 6, 2026, 7:00 AM EST - 6 months ago

Adial Pharmaceuticals Proxy statement: Proxy filing

Adial Pharmaceuticals Proxy statement: Proxy filing

Dec 23, 2025, 7:00 AM EST - 6 months ago

Adial Pharmaceuticals Proxy statement: Proxy filing

Adial Pharmaceuticals Registration statement: Registration filing

Dec 12, 2025, 7:00 AM EST - 6 months ago

Adial Pharmaceuticals Registration statement: Registration filing

Adial Pharmaceuticals announces $2.86M warrant inducement transaction

2025-11-26T13:05:42.000Z - 7 months ago

Adial Pharmaceuticals announces $2.86M warrant inducement transaction

Adial Pharmaceuticals reports Q3 net loss $1.8M vs $2.2M last year

2025-11-14T13:35:16.000Z - 7 months ago

Adial Pharmaceuticals reports Q3 net loss $1.8M vs $2.2M last year

Adial Pharmaceuticals Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 7 months ago

Adial Pharmaceuticals Quarterly report: Q3 2025

Adial Pharmaceuticals Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 7 months ago

Adial Pharmaceuticals Earnings release: Q3 2025

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

Oct 17, 2025, 9:00 AM EDT - 8 months ago

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

Adial Pharmaceuticals partners with Genomind for Precision Medicine Testing

2025-10-09T12:40:33.000Z - 9 months ago

Adial Pharmaceuticals partners with Genomind for Precision Medicine Testing

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Oct 9, 2025, 8:30 AM EDT - 9 months ago

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Adial Pharmaceuticals upgraded to Buy from Hold at Maxim

2025-09-30T11:40:10.000Z - 9 months ago

Adial Pharmaceuticals upgraded to Buy from Hold at Maxim

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

Sep 16, 2025, 8:00 AM EDT - 10 months ago

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Sep 3, 2025, 8:30 AM EDT - 10 months ago

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 11 months ago

Adial Pharmaceuticals Quarterly report: Q2 2025

Adial Pharmaceuticals Earnings release: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 11 months ago

Adial Pharmaceuticals Earnings release: Q2 2025

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Aug 6, 2025, 8:00 AM EDT - 11 months ago

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement

Jul 16, 2025, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

Adial Pharmaceuticals Proxy statement: Proxy filing

Jun 27, 2025, 8:00 AM EDT - 1 year ago

Adial Pharmaceuticals Proxy statement: Proxy filing

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Adial Pharmaceuticals Proxy statement: Proxy filing

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Adial Pharmaceuticals Proxy statement: Proxy filing

Adial Pharmaceuticals Registration statement: Registration filing

Jun 13, 2025, 8:00 AM EDT - 1 year ago

Adial Pharmaceuticals Registration statement: Registration filing

Adial Pharmaceuticals Proxy statement: Proxy filing

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Adial Pharmaceuticals Proxy statement: Proxy filing

Adial Pharmaceuticals Registration statement: Registration filing

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Adial Pharmaceuticals Registration statement: Registration filing

Adial Pharmaceuticals Registration statement: Registration filing

May 30, 2025, 8:00 AM EDT - 1 year ago

Adial Pharmaceuticals Registration statement: Registration filing

Adial Pharmaceuticals Proxy statement: Proxy filing

May 23, 2025, 8:00 AM EDT - 1 year ago

Adial Pharmaceuticals Proxy statement: Proxy filing

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Adial Pharmaceuticals Quarterly report: Q1 2025

Adial Pharmaceuticals Earnings release: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Adial Pharmaceuticals Earnings release: Q1 2025

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

May 13, 2025, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

May 2, 2025, 11:48 AM EDT - 1 year ago

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

May 1, 2025, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Mar 4, 2025, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Adial Pharmaceuticals Annual report: Q4 2024

Mar 4, 2025, 7:00 AM EST - 1 year ago

Adial Pharmaceuticals Annual report: Q4 2024

Adial Pharmaceuticals Earnings release: Q4 2024

Mar 4, 2025, 7:00 AM EST - 1 year ago

Adial Pharmaceuticals Earnings release: Q4 2024

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Feb 25, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Feb 19, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Feb 12, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jan 29, 2025, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Registration statement: Registration filing

Dec 20, 2024, 7:00 AM EST - 1 year ago

Adial Pharmaceuticals Registration statement: Registration filing

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Dec 3, 2024, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Adial Pharmaceuticals Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Adial Pharmaceuticals Quarterly report: Q3 2024

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Nov 5, 2024, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Adial Pharmaceuticals Proxy statement: Proxy filing

Sep 27, 2024, 8:00 AM EDT - 1 year ago

Adial Pharmaceuticals Proxy statement: Proxy filing

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals Quarterly report: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Adial Pharmaceuticals Quarterly report: Q2 2024

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Aug 7, 2024, 9:00 AM EDT - 2 years ago

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Jul 31, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jul 23, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

May 29, 2024, 8:30 AM EDT - 2 years ago

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 15, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals Quarterly report: Q1 2024

May 14, 2024, 8:00 AM EDT - 2 years ago

Adial Pharmaceuticals Quarterly report: Q1 2024

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Apr 22, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Adial Pharmaceuticals Registration statement: Registration filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Adial Pharmaceuticals Registration statement: Registration filing

Adial Pharmaceuticals posts promising update on alcohol disorder drug

Apr 10, 2024, 2:15 PM EDT - 2 years ago

Adial Pharmaceuticals posts promising update on alcohol disorder drug

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Apr 10, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Apr 2, 2024, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Adial Pharmaceuticals Annual report: Q4 2023

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Adial Pharmaceuticals Annual report: Q4 2023

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Mar 1, 2024, 7:00 PM EST - 2 years ago

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Feb 28, 2024, 9:30 AM EST - 2 years ago

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

Feb 15, 2024, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Feb 13, 2024, 9:15 AM EST - 2 years ago

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Jan 18, 2024, 8:30 AM EST - 2 years ago

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals Registration statement: Registration filing

Jan 12, 2024, 7:00 AM EST - 2 years ago

Adial Pharmaceuticals Registration statement: Registration filing

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

Dec 20, 2023, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

Adial Pharmaceuticals Proxy statement: Proxy filing

Dec 15, 2023, 7:00 AM EST - 2 years ago

Adial Pharmaceuticals Proxy statement: Proxy filing

Adial Pharmaceuticals Proxy statement: Proxy filing

Dec 8, 2023, 7:00 AM EST - 2 years ago

Adial Pharmaceuticals Proxy statement: Proxy filing

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Nov 29, 2023, 4:05 PM EST - 2 years ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

blackmajic31
blackmajic31 Jun. 24 at 11:51 AM
$ADIL
0 · Reply
StayPresent
StayPresent Jun. 23 at 7:18 PM
$ADIL I think Claiborne might be waiting for reparations or something to help fund this pos company.
1 · Reply
brallt
brallt Jun. 22 at 2:19 PM
$ADIL She gets Jucy over 3.20.
1 · Reply
Freeton
Freeton Jun. 18 at 7:39 PM
$ADIL why?
0 · Reply
brallt
brallt Jun. 18 at 5:15 PM
$ADIL about a 10% move to 3$ resistance.
0 · Reply
brallt
brallt Jun. 18 at 4:26 PM
$ADIL around time for todays accumulation. giving a bit more for lunch to be over.
0 · Reply
specctham
specctham Jun. 18 at 2:02 PM
$ADIL I want to buy a shitload of shares in this, but im scared.
0 · Reply
brallt
brallt Jun. 17 at 5:47 PM
$ADIL # fomo, am i not going to get my dip?.....
0 · Reply
Vibration
Vibration Jun. 17 at 5:16 PM
$ADIL it should pop in 5 min or back to the scalp !
0 · Reply
brallt
brallt Jun. 17 at 5:10 PM
$ADIL keep an eye out for a short attack to buy more before the move over 3 comes.
0 · Reply
Vibration
Vibration Jun. 17 at 5:09 PM
$ADIL going WILD ! just 60k shares in 5 min !
0 · Reply
Vibration
Vibration Jun. 17 at 5:02 PM
$ADIL wakes up !now
0 · Reply
blackmajic31
blackmajic31 Jun. 17 at 4:29 PM
$ADIL 💚
0 · Reply
Magic8BallResponse
Magic8BallResponse Jun. 17 at 2:10 PM
$ADIL Would love to see this at $2!!!!
0 · Reply
brallt
brallt Jun. 16 at 7:53 PM
$ADIL Just accumulate a few hundred here, a few hundred there, with market buys and she should move over 3$ this week. Take advantage of shorts and impatient sellers.
0 · Reply
Mikemelga2024
Mikemelga2024 Jun. 16 at 7:25 PM
$ADIL WTF? 🤷‍♂️
0 · Reply
brallt
brallt Jun. 16 at 5:20 PM
$ADIL snaged a few thousand at these levels. Under 3$ is a gift.
0 · Reply
Patrik605
Patrik605 Jun. 16 at 4:45 PM
$ADIL Investors are blind and do not see the potential of this company. 😶
1 · Reply
Jobsworth
Jobsworth Jun. 16 at 4:39 PM
$ADIL shorting bott is trying to very hard too shake out cover shares below $3
0 · Reply
2TrustHim
2TrustHim Jun. 16 at 10:37 AM
$ADIL Filing F-3 Might Mean They Are Preparing Buys Or Sells Correct?Don't Want To Miss An Explosive Move!!!
0 · Reply
deframel1011
deframel1011 Jun. 15 at 5:15 PM
$RGNT come to $ADIL , another stock that will go up 10x. I made 80k on RGNT today :)
0 · Reply
deframel1011
deframel1011 Jun. 15 at 4:53 PM
$ADIL no volume
0 · Reply